Eli Lilly (LLY) PT Raised to $420 at Credit Suisse
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Price: $1,280.34 +4.46%
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
30 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Credit Suisse analyst Trung Huynh raised the price target on Eli Lilly (NYSE: LLY) to $420.00 (from $400.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
